Notably, the activation of p38 MAPK, which is involved in tau phosphorylation at pathogenic residues and is positively correlated with the amount of aggregated tau, has been well established in the brains of AD mouse models and patients during early stage of disease [37–40]. This evidence concerns the gene MAPT and Alzheimer disease.